Recent Updates
Recently added Catalysts
ZTS Positive Sentiment

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wednesday, July 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zoetis Inc. has launched Portela® (relfovetmab) in Canada and the EU, marking a significant advancement in veterinary medicine. This therapy is the first long-acting monoclonal antibody designed to relieve pain from osteoarthritis in cats, providing relief for up to three months with just one injection. The launch is supported by extensive research and development.
Price reaction · baseline $75.35 (2026-07-21 close) · hit pre-market · clean, no other ZTS news in the window
day 0 close · peak
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of Portela® marks a significant advancement in animal health.
  • First long-acting mAb therapy for cats to alleviate osteoarthritis pain.
  • Effective pain relief for up to three months with a single injection.

Full Press Release Details

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in al

Frequently Asked Questions

What is Portela® (relfovetmab)?

Portela® is a long-acting monoclonal antibody therapy for cats, targeting osteoarthritis pain.

How long does Portela® provide pain relief?

Portela® offers pain relief for up to three months with a single subcutaneous injection.

In which regions has Portela® been launched?

Portela® has been launched in Canada and European Union member states.

What condition does Portela® treat in cats?

Portela® is designed to alleviate pain associated with osteoarthritis in cats.

ShareAdd on Google
Tags: ZTS Viatris Investor Conferences Healthcare Zoetis Portela relfovetmab animal health osteoarthritis
Last updated: Jul 22, 2026

Biotech snapshot

Cash runway
$1676M liquidity · $0M/mo burn
Low dilution risk